A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.
The guidelines, published online today in a paper in JAMA Oncology, recommend discontinuing routine mammograms for survivors with a life expectancy under five years; considering stopping screening for those with a 5-10-year life expectancy; and continuing mammography for those whose life expectancy is greater than 10 years. The guidelines will be complemented by printed materials to help survivors gauge their risk of cancer recurring in the breast and weigh the potential benefits and drawbacks of mammography with their health care team.
Rachel A. Freedman, MD, MPH
“The standard recommendation for mammography in breast cancer survivors of all ages has been annual screening. There has been little guidance on how to tailor screening for older survivors – what role life expectancy, risk of recurrence, patient preferences, or the tradeoffs associated with mammography should play,” says Rachel A. Freedman, MD, MPH, of Dana-Farber Cancer Institute, the first author of the new paper. “The result is that the use of mammography for older survivors has been highly inconsistent. With the number of older women who will be diagnosed with breast cancer expected to increase in the coming years, it’s important that we find ways to individualize decisions for each patient’s circumstances and preferences.”
To formulate the new guidelines, Freedman recruited an 18-member panel of patients in addition to breast cancer primary care, geriatrics, radiology, survivorship, and nursing experts from around the country to review the scientific literature on the risk of in-breast cancer among older breast cancer survivors, taking into account the subtype of cancer, the treatment patients received, their age, and health status. The group conducted a parallel review of research on the benefits and downsides of mammography. (Designed to detect breast cancer at an early stage, mammograms sometimes uncover growths that turn out not be cancerous, or small, slow-growing tumors that won’t have an impact on an older woman’s life expectancy. The detection of such growths often entails further stress and anxiety, tests, and treatment.)
Reassuringly, the literature review confirmed that most older breast cancer survivors had a low risk for breast cancer in either breast – particularly for those who had been treated with hormone-blocking therapy for hormone receptor-positive tumors. The panel estimated older survivors’ risk of developing cancer in the breast over a 10-year period and organized their results by cancer type and treatment.
The review of mammography studies found that although the benefits of screening in older women are not well defined, research suggests mammography offers little to modest clinical benefit for many older women. The main downsides of mammography were false-positives (detection of growths that appear cancerous but turn out not to be), anxiety associated with diagnostic testing, and overtreatment.
Combining the results of these reviews, the panel formulated a series of mammography guidelines for survivors of breast cancer. The guidelines were considered by a group of clinicians and patient advocates and by five clinician focus groups, resulting in several revisions. After further review by the International Society for Geriatric Oncology, the guidelines were refined and finalized.
Because of the low risk that older survivors will develop a cancer in their breast, the lengthy time needed for the small benefits of mammography to be realized, and the persistence of the negative effects of mammography, the new guidelines recommend discontinuing mammography for breast cancer survivors age 75 or older whose life expectancy is under five years. This holds even for those with a history of higher-risk tumors such as triple-negative or ERBB2-positive. (Life expectancy is estimated by factors such as an individual’s medical history, their degree of functional independence, whether they smoke cigarettes, had a fall in the previous year, and whether they were recently hospitalized.) The guidelines call for consideration of stopping mammography when life expectancy is five to 10 years and continuing annual or biennial mammography when life expectancy exceeds 10 years. For women age 85 and older, whose life expectancy is often under five years, the guidelines recommend ceasing mammography unless an individual is in extraordinary health and has a strong preference to continue testing.
Freedman emphasizes that the new guidelines are not prescriptive but should serve as a starting point for older survivors of breast cancer in conversations with their physician. “The purpose of the guidelines is to offer clinicians support for having these conversations with patients and to make a shared, individualized decision for each woman,” she says.
The senior authors of the paper are Nancy L. Keating, MD, MPH, of Brigham and Women’s Hospital, and Mara A. Schonberg, MD, MPH, of Beth Israel Deaconess Medical Center. Co-authors are: Eric P. Winer, MD, Haley Gagnon, Adriana Perilla-Glen, MBA, Nancy U. Lin, MD, and Anna C. Revette, PhD, of Dana-Farber; Barbara K. LeStage, MHP, of Dana-Farber and the Alliance for Clinical Trials in Oncology; Christina A. Minami, MD, MFA, MS, of Brigham and Women's Hospital; Monica Morrow, MD, and Stuart M. Lichtman, MD, of Memorial Sloan Kettering Cancer Center; Alexander K. Smith, MD, MS, MPH, and Louise C. Walter, MD, of Veterans Affairs Health Care System, San Francisco, Calif.; Mina S. Sedrak, MD, MS, of City of Hope; Hans Wildiers, MD, of University Hospitals, Leuven, Belgium; Tanya M. Wildes, MD, MDSI, of Washington University School of Medicine; Kah Poh Loh, MBBCh, BAO, of University of Rochester School of Medicine and Dentistry; Etienne G. C. Brain, MD, PhD, of Institut Curie, Saint-Cloud, France; Pamela S. Ganschow, MD, of Rush University Medical College and Cook County Health; Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center; Deborah K. Mayer, PhD, RN, AOCN, of University of North Carolina at Chapel Hill; Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic; and Reshma Jagsi, MD, DPhil, of the University of Michigan; Beverly Canin, of the Cancer and Aging Research Group.
The study was supported by the National Cancer Institute (grants R21CA227615-01A1 and P30 CA00874.8); Susan G. Komen (CCRCR18552788); the American Cancer Society (MRSG-14-240-01-CPPB); and the National Institute on Aging (P30 AG044281.
